Ken Griffin Annovis Bio, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,800 shares of ANVS stock, worth $90,958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,800
Previous 152,500
88.33%
Holding current value
$90,958
Previous $878,000
83.71%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ANVS
# of Institutions
46Shares Held
1.17MCall Options Held
229KPut Options Held
934K-
Vanguard Group Inc Valley Forge, PA380KShares$1.94 Million0.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$514,6220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.1KShares$506,4720.0% of portfolio
-
Group One Trading, L.P. Chicago, IL52.8KShares$269,6390.02% of portfolio
-
Quest Partners LLC New York, NY46KShares$235,0700.03% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $41.7M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...